Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059843) titled 'DaraPIONEER (Japan): Panel Interview of ONcology practices with Emergent Experience of Daratumumab in the Real World (Japan)' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Newly Diagnosed Multiple Myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To characterize the multifaceted convenience and real-world value proposition of Daratumumab subcutaneous (SC)-based regimens for the treatment of transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) from the perspective of Japa...